(Q35665871)

9 August 2017

title

Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy (English)

1 reference

enzyme replacement therapy

9 August 2017

main subject

0 references

13

Futoshi Shibasaki

1 reference

9 August 2017

Sachie Nakano

1

1 reference

9 August 2017

Takahiro Tsukimura

2

1 reference

9 August 2017

Tadayasu Togawa

3

1 reference

9 August 2017

Toya Ohashi

4

1 reference

9 August 2017

Masahisa Kobayashi

5

1 reference

9 August 2017

Katsuyoshi Takayama

6

1 reference

9 August 2017

Yukuharu Kobayashi

7

1 reference

9 August 2017

Hiroshi Abiko

8

1 reference

9 August 2017

Masatsugu Satou

9

1 reference

9 August 2017

Tohru Nakahata

10

1 reference

9 August 2017

David G Warnock

11

1 reference

9 August 2017

Hitoshi Sakuraba

12

1 reference

9 August 2017

language of work or name

English

0 references

publication date

17 June 2015

1 reference

9 August 2017

1 reference

9 August 2017

volume

10

1 reference

9 August 2017

issue

6

1 reference

9 August 2017

page(s)

e0128351

1 reference

Creative Commons Attribution 4.0 International

9 August 2017

copyright license

start time

17 June 2015

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Agalsidase benefits renal histology in young patients with Fabry disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Reliability of a newly-developed immunochromatography diagnostic kit for pandemic influenza A/H1N1pdm virus: implications for drug administration

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Updated values for molecular diagnosis for highly pathogenic avian influenza virus

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Fabry disease, enzyme replacement therapy and the significance of antibody responses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Sensitivity of influenza rapid diagnostic tests to H5N1 and 2009 pandemic H1N1 viruses

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4470989

25 September 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0128351

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26083343

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The immunogenicity of therapeutic proteins and the Fabry antibody standardization initiative

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26083343

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1371/JOURNAL.PONE.0128351

1 reference

release_272ki53uebfrla5pmlhu3tpr5e

9 August 2017

0 references

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/272ki53uebfrla5pmlhu3tpr5e

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

4470989

1 reference

9 August 2017

1 reference